-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Huahai and Kyushu Tong jointly sold the Ubershatan tabletsNovember 26, Kyushu Tong announced that Kyushu Tong and Huahai Pharmaceutical Sholding Subsidiary Huahai Pharmaceuticals signed the "Strategic Cooperation Framework Agreement" on November 25, 2019, Huahai Pharmaceuticals will take it with the national organization The winning varieties in the pilot expansion of volume procurement, "Ebeshatan tablets" in addition to the 4 plus 7 band of procurement cities and Fujian, Hebei hospitals outside the full channel sales, all entrusted to the company, and Kyushu Tong is also responsible for the sale of the channel and in the alliance procurement of selected provinces of medical distribution protectionit is understood that the original drug of Theochasatan tablets is Sanofi's Amberway, which was approved by the FDA in 1997 and has been listed in 75mg, 150mg and 300mgThe indications of "Ebesatan tablets" are for the treatment of primary hypertension, combined with hypertension of type 2 diabetes kidney diseaseIn the alliance procurement (4 plus 7 expansion), Huahai Pharmaceutical's Ebeshatan tablets again won the bid, the number of bids as follows:4 and 7 expanded Chinese sea medicine Erbeshatan tablets again winning the bid
Kyushu Tong said, this cooperation with Huahai Pharmaceuticals sales target of 900 million The agreement is valid from November 1, 2019 to December 31, 2020, from November 1, 2019 to December 31, 2020, the winning list (the winning list is 137 million tablets, including 75mg and 150mg specifications)announcement shows that the two sides have started to further expand cooperation in November 2019, establish strategic cooperative relations and achieve win-win goalsIn the 2020 agreement, Huahai Pharma is responsible for the full channel sales of 900 million pieces to Kyushu Tong's annual sales target (Kyushu Tong is responsible for all channels except for the 4 plus 7 band purchase cities, Fujian and Hebei hospitals)Purchases in November and December 2019 are included in the 2020 Agreement)in the 4 plus 7 expansion, Huahai Pharmaceutical's Ebeshatan tablets proposed to win the number of about 250 million, not counting the first batch of the purchase of the winning number, Huahai Pharmaceuticals and Kyushu Tong co-sales of 900 million pieces of procurement volume, basically the market outside the collection alliance is covered, and in this expansion, in addition to Huahai, Hengrui, Hanyu also Ebeshatan film the same winning bidAmong them, hanxuan's quotation is lower than that of HuahaiI do not know, the next including Hengrui, Hanyu and other winning enterprises in the sales channels will be how the layoutsqueeze the outside market space
Sina Pharma previously on September 1 joint lying "Union Regional Drug Purchase Collection collection Chinese" procurement rules made an analysis, 25 selected varieties of the first year of the agreed procurement volume is in accordance with 50%, 60%, 70% of the proportion of the specific quantity, that is, the exclusive winning bid to obtain 50% share, 2 to get 60%, 3 to get 70% shareIdeally, the winning company can also compete for the remaining 30% to 50% of the marketThis market is about the survival of the bid enterprise After the expansion of the 4 plus 7, the out-of-standard market has also been a topic of concern in the industry Now, Huahai's cooperation with Kyushu Tong refers to the "4 plus 7" with volume procurement city and Fujian, Hebei hospital outside the full channel, and mentioned that will guarantee the Ebeshatan tablets in the alliance procurement of selected provinces of medical distribution This move opened the winning enterprise layout of the off-hospital sales market, to the unbid enterprise son can imagine the challenge, the remaining market of the winning enterprise? The impact of the policy on the generic drug industry is not to be underestimated Although this announcement mentions that the annual agreement agreed in this Agreement is intended to be the goal set by both parties in accordance with the vision of cooperation, and that there may be uncertainty as to whether the expected objectives can be achieved at a later stage subject to policy and market environmental impacts But Huahai as a raw material drug factory, basically do not worry about the shortlisted varieties how to ensure the supply, on the contrary, Huahai this move has to use the influence of 4 plus 7 expansion of the variety of the market to further expand, with the advantages of Kyushu Tong in the circulation of drugs, multi-directional coverage of sales channels, which has been selected for the same varieties and no winning varieties, will pose a huge challenge as the country pushes 4 plus 7, the future generic head enterprise advantage will clearly win, the new super giant smaller or will be formed; At the moment, this trend is accelerating.